AB1095 IMPACT OF PSORIATIC ARTHRITIS MANIFESTATIONS ON PERCEPTION OF PAIN IMPROVEMENT: POOLED ANALYSIS OF TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES WITH GUSELKUMAB

Background Pain in PsA has multifaceted origins (e.g., peripheral joint inflammation, axial involvement [axPsA], skin lesions, dactylitis, enthesitis, underlying conditions) and can be difficult to treat. Guselkumab (GUS), a fully human IL-23p19 subunit inhibitor, is effective treating multiple domains elicited durable improvement patient (pt)-reported pain (PtP) the DISCOVER (D)-1&2 trials [1,2] . Objectives Assess association between key manifestations PtP using 1-year D1&2 data. Methods enrolled adults with active despite standard therapies [3,4] Pts were randomized 1:1:1 GUS 100 mg every 4 weeks (Q4W); at W0, W4, then Q8W; or placebo crossover Q4W W24. Treatment groups pooled (N=1120). Longitudinal associations of SJC (0-66), TJC (0-68), Leeds enthesitis index (LEI), dactylitis severity score (DSS), Psoriasis Area Severity Index (PASI), axPsA (N=312), overall (0-100 mm) spinal (BASDAI question 2 pts axPsA) assessed. these ≥30%/50%/70% improvements (PtP-30/50/70) Results Mean (SD) BL 61.2 (19.8) indicated substantial burden. Upon adjusting for potential confounders, greater PASI, SJC, (mutually adjusted) each associated significantly higher odds achieving PtP-30 through W52 (Table 1 ). PASI reduction was also PtP-50, as PtP-50/70. In LEI, attaining PtP-30/50/70; only PtP-30. reductions improvement. Overall, presence did not impact extent (data shown). axPsA, significant observed LEI Conclusion Improvements reduction, although varying extents. had greatest on improvement, likely due overlap construct measured. relief than highlighting sensory burden while showed both relief. These findings underscore importance utilizing treatments across address recalcitrant symptoms. References [1]Ritchlin CT. RMD Open 2022;8:e002195 [2]Nash P. ACR Convergence 2021 (PO1333) [3]Deodhar A. Lancet 2020;395:1115 [4]Mease PJ. 2020;395:1126 Table 1. Adjusted Associations Between Key Manifestations Improvement Through Pt Population Predictor (Δ) Δ (β) Odds Ratio (OR) 3 Spinal 2,4 PtP-50 PtP-70 All (N=1120 ) 0.41 ‡ 1.05 † 1.04 0.03 0.28 1.03 * 1.06 0.55 1.08 1.12 0.06 Enthesitis (N=728 1.62 1.19 1.25 1.32 0.18 0.47 0.02 0.39 0.05 Dactylitis (N=473 DSS -0.04 0.97 1.01 1.07 0.01 0.31 0.19 1.02 0.60 1.11 p<0.05; p<0.01; p≤0.0001 values, age, gender, BMI, SF-36 Mental Component Summary score, – ≥7 (central sensitization proxy), FACIT-Fatigue treatment group β correspond incremental increase improvement; ORs endpoints, (vs absence) axPsA. Higher = N=312 Acknowledgements: NIL. Disclosure Interests Peter Nash Consultant of: AbbVie, Boehringer-Ingelheim, Eli Lilly, Gilead/Galapagos, GSK, Janssen, MSD, Novartis, Pfizer, Samsung, Sun Pharma, UCB, Grant/research support from: Iain McInnes Shareholder Causeway Therapeutics Evelo Compugen, Amgen, Astra Zeneca, Bristol-Myers Squibb, Cabaletta, Gilead, Roche, Sanofi, Christopher T. Ritchlin Lai-Shan Tam Enrique Soriano Speakers bureau: Michael Starr Emmanouil Rampakakis Employee JSS Medical Research, Inc., Frederic Lavie Johnson & Johnson, Immunology Global Affairs, Janssen Pharmaceutical Companies May Shawi Xenofon Baraliakos Biocad, Chugai, Philip J Mease Aclaris, Galapagos, Inmagene, Bristol Myers UCB.